公开(公告)号：US12076368B2

公开(公告)日：2024-09-03

申请号：US16097072

申请日：2017-04-28

Applicant: Novozymes A/S

Inventor： Peter Nordkild ,  Soren Kjaerulff

IPC: A61K38/17 ,  A61K9/00 ,  A61K38/04 ,  A61K38/26 ,  A61P1/16 ,  A61P1/18 ,  A61P3/00 ,  A61K45/06

CPC classification number: A61K38/1729 ,  A61K9/0053 ,  A61K38/04 ,  A61K38/26 ,  A61P1/16 ,  A61P1/18 ,  A61P3/00 ,  A61K45/06 ,  A61K38/04 ,  A61K2300/00 ,  A61K38/1729 ,  A61K2300/00 ,  A61K38/26 ,  A61K2300/00

Abstract: The present invention relates to methods for treatment or prevention of liver, biliary tract, and pancreatic disorders by administering one or more defensins. Included within the scope of the disclosure is also treatment of certain metabolic disorders.

公开(公告)号：US11413328B2

公开(公告)日：2022-08-16

申请号：US16468051

申请日：2017-12-13

Applicant: Novozymes A/S

Inventor： Peter Nordkild ,  Søren Kjærulff

IPC: A61K38/17 ,  A61P11/06 ,  A61K9/00 ,  A61K38/38 ,  A61K45/06

Abstract: The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian α- and/or β-defensin.